InvestorsHub Logo
Followers 466
Posts 26938
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 318

Thursday, 04/18/2013 9:43:11 AM

Thursday, April 18, 2013 9:43:11 AM

Post# of 506
7:18AM Sinovac Biotech EV71 vaccine Phase III top-line results presented at 13th Annual World Vaccine Congress & Expo; data indicated that our EV71 vaccine had 95% efficacy against EV71-associated HFMD /herpangina, and 100% efficacy against EV71-associated hospitalization (SVA) 4.13 : Co announced that Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, presented data regarding Sinovac's proprietary enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD") at the 13th Annual World Vaccine Congress & Expo, taking place from April 16-18, 2013, in Washington D.C. Dr. Fengcai Zhu acted as a co-principal investigator in Sinovac's phase III trial for its EV71 vaccine.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SVA News